title: IGF axis gene expression patterns are prognostic of survival in epithelial ovarian cancer.
abstract: The IGF axis has documented growth-promoting effects in various malignancies, but its role in epithelial ovarian cancer (EOC) has not been adequately examined. We studied the expression of the IGF axis genes in relation to outcome in EOC. Microarray expression profiles from 64 patients with advanced-stage EOC were used. Two multi-gene subsets were chosen, one upstream of the IGF receptor ('IGF family') and the other downstream of the IGF receptor ('IGF signaling pathway'), and analyzed in relation to survival. In addition, expression patterns of the two gene subsets were analyzed in relation to favorable and unfavorable prognosis categories identified in a previous study by whole-genome expression profiling. In a gene-by-gene analysis, IGF binding protein 4 and IGF-II receptor gene expression was inversely associated with survival. Using hierarchical clustering, the two multi-gene subsets separated the patient cohort into two groups with different median survival (IGF family: 33 vs 63 months, P=0.02 and IGF signaling pathway: 41 vs 63 months, P=0.05). Furthermore, the two multi-gene subsets were differentially expressed between the previously defined favorable and unfavorable prognosis tumors (Kolmogorov-Smirnov permutation: P=0.0005 and 0.003 for the IGF family and signaling pathway respectively), and individual genes (including IGF-I, IGF-I receptor, and several genes downstream of the receptor) were overexpressed in unfavorable prognosis tumors (permutation P<0.05). The expression patterns of several genes in the IGF axis are associated with survival in EOC, and expression changes of these genes may be underlying previously proposed microarray-derived clinical prognostic models. Future studies are needed to more precisely determine the diagnostic and potential therapeutic significance of these findings.
authors.affiliation: Gynecologic Medical Oncology Program, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA.
authors.forename: Dimitrios
authors.initials: D
authors.lastname: Spentzos
authors.forename: Stephen A
authors.initials: SA
authors.lastname: Cannistra
authors.forename: Franck
authors.initials: F
authors.lastname: Grall
authors.forename: Douglas A
authors.initials: DA
authors.lastname: Levine
authors.forename: Kamana
authors.initials: K
authors.lastname: Pillay
authors.forename: Towia A
authors.initials: TA
authors.lastname: Libermann
authors.forename: Christos S
authors.initials: CS
authors.lastname: Mantzoros
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D008040:Genetic Linkage; D006801:Humans; D008875:Middle Aged; D008954:Models, Biological; D005810:Multigene Family; D015999:Multivariate Analysis; D009375:Neoplasms, Glandular and Epithelial / Q000175:diagnosis* / Q000235:genetics / Q000401:mortality; D020411:Oligonucleotide Array Sequence Analysis; D010051:Ovarian Neoplasms / Q000175:diagnosis* / Q000235:genetics / Q000401:mortality; D011379:Prognosis; D015398:Signal Transduction / Q000235:genetics*; D013002:Somatomedins / Q000235:genetics*; D016019:Survival Analysis
chemical_list: D013002:Somatomedins